Toripalimab Combo Delivers Long-Term Efficacy in Nasopharyngeal Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Toripalimab Combo Delivers Long-Term Efficacy in Nasopharyngeal Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Apr 4, 2025
targetedonc.com
#junshibiosciences #toripalimab #pd1 #nasopharyngealcarcinoma #lungcancer #immunotherapy #chinapharma #biotechpipeline #oncology #drugdevelopment #pharmaceuticaldistribution #globalpharma… | 骆佳渝 Camellia
#junshibiosciences #toripalimab #pd1 #nasopharyngealcarcinoma #lungcancer #immunotherapy #chinapharma #biotechpipeline #oncology #drugdevelopment #pharmaceuticaldistribution #globalpharma… | 骆佳渝 Camellia
1 month ago
linkedin.com
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
5 months ago
marketscreener.com
Treatment Landscape of Recurrent NPC: Evaluating First-Line Toripalimab in the Recurrent Setting | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Treatment Landscape of Recurrent NPC: Evaluating First-Line Toripalimab in the Recurrent Setting | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Mar 13, 2025
targetedonc.com
Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Mar 14, 2025
targetedonc.com
DIAMOND: toripalimab & radiotherapy in nasopharyngeal carcinoma without cisplatin
6:09
DIAMOND: toripalimab & radiotherapy in nasopharyngeal carcinoma without cisplatin
391 views11 months ago
YouTubeVJOncology
LOQTORZI (toripalimab) : Nouveau traitement pour le carcinome nasopharyngé (CNP)
6:26
LOQTORZI (toripalimab) : Nouveau traitement pour le carcinome nasopharyngé (CNP)
11 views3 months ago
YouTubePharmaide
Initial Insights From JUPITER-02 - Toripalimab Efficacy in R/M NPC | OncLive
11 months ago
onclive.com
Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint
May 7, 2023
marketscreener.com
Junshi Biosciences Announces Toripalimab's NDA Accepted by the Singapore Health Sciences Authority
Feb 1, 2024
finanznachrichten.de
0:18
Proud to announce the launch of Toripalimab in India, the first and only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab is a New Biological Entity (NBE). The combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death, meeting a significant unmet need for p
245 viewsNov 28, 2024
FacebookDr. Reddy's Laboratories Ltd.
Toripalimab FLOT Regimen Improves Gastric Cancer Outcomes | Gunjan Desai posted on the topic | LinkedIn
19.9K views4 months ago
linkedin.com
Dr Yuan on 3-Year Data for Perioperative Toripalimab/Chemo in Gastric/GEJ Cancer | OncLive
4 months ago
onclive.com
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
Mar 23, 2025
thespec.com
30:00
Transforming Nasopharyngeal Carcinoma Care: The Role of Immunotherapy
800 viewsNov 13, 2024
YouTubeMedscape
1:26
Toripalimab #How is it different
95 views7 months ago
YouTubeCancer education made simple # Chandrakant…
5:28
What Is The Moa Of Loqtorzi Toripalimab
89 viewsJul 18, 2024
YouTubeRX Card Club
Molecular Dynamics Simulation to Investigate the Blockade Mechanism of Anti-PD-1 Antibody Toripalimab | Proceedings of the 2021 11th International Conference on Biomedical Engineering and Technology
2 months ago
acm.org
Toripalimab Boosts Lung Cancer Survival in Stage III NSCLC Trial | Aadil Najeed posted on the topic | LinkedIn
5 views2 months ago
linkedin.com
2:52
New cancer medicine Immunotherapy for Head & Neck, Esophageal, Gastric & Lung Cancer | Dr Pratik ...
6.7K viewsDec 17, 2024
YouTubeDr. Pratik Patil Oncologist
Loqtorzi: Cost, Dosage, Side Effects, Interactions, and More
6 months ago
HealthlineKristi Laxson,PharmD
Coherus BioSciences obtient l'examen prioritaire de la FDA pour le traitement du carcinome par anticorps monoclonal toripalimab
10 months ago
zonebourse.com
4:12
Chidamide plus toripalimab shows promise in advanced sarcoma
13 views7 months ago
YouTubeVJOncology
16:29
The PBS Update March 2026: Landmark Ipi–Nivo Listing + Toripalimab and Cabozantinib
52 views2 months ago
YouTubeThe Oncology Network
4:47
Disitamab vedotin & neoadjuvant toripalimab for MIBC in the RC48-C017 trial
93 viewsFeb 28, 2025
YouTubeVJOncology
1:40
Two drugs can give the SAME effect… but one needs a much smaller dose 😳 #toripalimab #momelotinib
47 views1 month ago
YouTubeNURSING STUDENTS STUDY GUIDE
1:20
INDO404 Drug Not Found : Toripalimab #pharmacist
1.6K views1 month ago
YouTubeSukma Purnama
2:22
NEOTORCH Trial: Perioperative Toripalimab for NSCLC - OncTalk Lung 2023
145 viewsApr 2, 2024
YouTubeGlobal Resource for Advancing Cancer Education
0:29
🚩 ICYMI! Nabil Saba, MD reminds that the JUPITER-02 trial's positive results led to an FDA approval in 2023 of combination toripalimab gemcitabine specifically for first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, which was more effective than chemotherapy alone. Watch Learn along with Jennifer Choe, MD ➡️ http://ms.spr.ly/6181WYXtx | Medscape Oncology
26 viewsNov 26, 2024
FacebookMedscape Oncology
特瑞普利单抗（Toripalimab）/拓益®注射液说明书
1 month ago
haodf.com
See more
Static thumbnail place holder